Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
ALUMIS INC. (ALMS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALMS at 7.1/100 on a 32-signal composite quality model, placing it at rank #2,948 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.7) and profitability (0.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ALUMIS INC. reports quarterly revenue of $1.7M, net income of $-142.2M, free cash flow of $-81.7M. Top institutional holders of ALMS by reported 13-F value include AyurMaya Capital Management Company, BlackRock, FMR, based on the most recent SEC filings. ALMS trades on the Nasdaq exchange and files with the SEC under CIK 1847367. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALUMIS INC. directly from SEC EDGAR.
AI Quality Score
7.1/100
AI Rank
#2,948
Revenue
$1.7M
Net Income
$-142.2M
Free Cash Flow
$-81.7M
| Period | Form | Revenue | Net income | Operating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $24.1M | $-243.3M | — |
| Institution | Shares | Value | Reported |
|---|---|---|---|
| AyurMaya Capital Management Company | 15,139,707 | $426.0M | 2026-06-30 |
| BlackRock | 8,218,151 | $231.3M | 2026-06-30 |
| FMR | 6,769,170 | $190.5M | 2026-06-30 |
| Deep Track Capital | 6,348,558 | $178.6M | 2026-06-30 |
| Samsara BioCapital | 6,345,219 | $178.6M | 2026-06-30 |
| Foresite Capital Management V | 5,896,995 | $165.9M | 2026-06-30 |
| PRICE T ROWE ASSOCIATES | 5,199,838 | $146.3M | 2026-06-30 |
| venBio Partners | 4,528,408 | $127.4M | 2026-06-30 |
| Foresite Capital Management VI | 4,247,670 | $119.5M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT | 4,215,703 | $118.6M | 2026-06-30 |
13F Pro Quality Score
Rank #2,948 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk